Exact Sciences Corp. (NASDAQ:EXAS) is a prominent player in the field of cancer screening tests, known for its innovative products like Cologuard. The company has recently been in the spotlight due to a significant acquisition announcement. Abbott Laboratories plans to acquire Exact Sciences for approximately $21 billion, offering $105 per share to its shareholders. This acquisition is expected to be completed in the second quarter of the following year.
On November 28, 2025, Stifel Nicolaus set a price target of $105 for EXAS. At that time, the stock was priced at $101.29, indicating a potential upside of about 3.66%. This aligns with Abbott's acquisition offer, which also values the stock at $105 per share. The acquisition news has positively impacted EXAS shares, which soared by 17% following the announcement.
Exact Sciences reported $851 million in revenue for the third quarter and has increased its full-year revenue forecast to between $3.22 billion and $3.235 billion. This strong financial performance underscores the company's growth potential, making it an attractive acquisition target for Abbott. The U.S. market for cancer screening and precision oncology diagnostics is valued at around $60 billion, as highlighted by Abbott, indicating significant growth opportunities.
Currently, EXAS is trading at $101.29, reflecting a slight decrease of 0.16, or approximately -0.16%. The stock has fluctuated between $101.16 and $101.54 today. Over the past year, EXAS has seen a high of $101.87 and a low of $38.81. With a market capitalization of approximately $19.19 billion, Exact Sciences remains a key player in the healthcare sector.
